BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome

Reuters12-11

Dec 11 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROME
RHYTHM PHARMACEUTICALS INC - PLANS PHASE 3 TRIAL FOR SETMELANOTIDE IN PWS
RHYTHM PHARMACEUTICALS INC: SAFETY AND TOLERABILITY RESULTS HAVE BEEN CONSISTENT WITH SETMELANOTIDE'S WELL-ESTABLISHED CLINICAL PROFILE
RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE SHOWS BMI AND HYPERPHAGIA REDUCTIONS IN PWS

Source text: ID:nGNX88c91t

Further company coverage: RYTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590513793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590513793","market":"nz","top_or_hot":-1,"title":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Rhythm Pharmaceuticals Inc <span>RYTM.O</span>:</p><ul><li><p>RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROME</p></li><li><p>RHYTHM PHARMACEUTICALS INC - PLANS PHASE 3 TRIAL FOR SETMELANOTIDE IN PWS</p></li><li><p>RHYTHM PHARMACEUTICALS INC: SAFETY AND TOLERABILITY RESULTS HAVE BEEN CONSISTENT WITH SETMELANOTIDE'S WELL-ESTABLISHED CLINICAL PROFILE</p></li><li><p>RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE SHOWS BMI AND HYPERPHAGIA REDUCTIONS IN PWS</p></li></ul><p>Source text: <span>ID:nGNX88c91t</span></p><p>Further company coverage: <span>RYTM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome</title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span>Rhythm Pharmaceuticals Inc <span>RYTM.O</span>:</p><ul><li><p>RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROME</p></li><li><p>RHYTHM PHARMACEUTICALS INC - PLANS PHASE 3 TRIAL FOR SETMELANOTIDE IN PWS</p></li><li><p>RHYTHM PHARMACEUTICALS INC: SAFETY AND TOLERABILITY RESULTS HAVE BEEN CONSISTENT WITH SETMELANOTIDE'S WELL-ESTABLISHED CLINICAL PROFILE</p></li><li><p>RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE SHOWS BMI AND HYPERPHAGIA REDUCTIONS IN PWS</p></li></ul><p>Source text: <span>ID:nGNX88c91t</span></p><p>Further company coverage: <span>RYTM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8XKP3F:1","article_id":"2590513793","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590513793","pubTimestamp":1765456451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi SyndromeDec 11 (Reuters) - Rhythm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技","RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"BRIEF-Rhythm Pharmaceuticals宣布探索性2期试验的初步数据显示Setmelanotide在Prader-Willi综合征中表现出积极的疗效信号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":0.9},"content_text":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi SyndromeDec 11 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROMERHYTHM PHARMACEUTICALS INC - PLANS PHASE 3 TRIAL FOR SETMELANOTIDE IN PWSRHYTHM PHARMACEUTICALS INC: SAFETY AND TOLERABILITY RESULTS HAVE BEEN CONSISTENT WITH SETMELANOTIDE'S WELL-ESTABLISHED CLINICAL PROFILERHYTHM PHARMACEUTICALS INC - SETMELANOTIDE SHOWS BMI AND HYPERPHAGIA REDUCTIONS IN PWSSource text: ID:nGNX88c91tFurther company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590513793","isCrawlerRequest":true}